Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06193928
Other study ID # MRX-310
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 21, 2023
Est. completion date September 20, 2028

Study information

Verified date March 2024
Source Mirum Pharmaceuticals, Inc.
Contact Clinical Trials Mirum
Phone +16506674085
Email Clinical Trials
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The goal of this observational study is to evaluate the long-term safety and clinical outcomes of Livmarli prescribed to patients with Alagille Syndrome (ALGS).


Description:

LivmarliĀ® is a novel, minimally absorbed, pharmacological treatment for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS), a rare, genetic, autosomal dominant, complex multisystem disorder characterized by the presence of cholestasis (typically presenting as jaundice in the neonatal period) due to intrahepatic bile duct paucity. Livmarli inhibits the ileal bile acid transporter (IBAT) in the terminal ileum, leading to reduced levels of bile acids, thereby improving clinical manifestations and symptoms of cholestasis. Livmarli has been developed by Mirum Pharmaceuticals and approved by the US Food and Drug Administration (FDA) for the treatment of cholestatic pruritus in patients with ALGS who are 3 months of age and older. To be eligible for the study, participants must meet the following criteria: - A clinically and/or genetically confirmed ALGS diagnosis - Participant prescribed Livmarli


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date September 20, 2028
Est. primary completion date September 20, 2028
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - A clinically and/or genetically confirmed ALGS diagnosis - Participant prescribed Livmarli Exclusion Criteria: - Refusal to provide informed consent/assent (if required by the local IRB) - Previously or currently on Livmarli through participation in a clinical study or expanded access program - Participants who have previously received an SBD or LT - Any condition or abnormalities that, in the opinion of the investigator, may interfere with the participant participating in or completing the study - Participants who have received an investigational drug within 30 days of the first dose of Livmarli

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Maralixibat
The recommended dosage is 380 mcg/kg once daily.

Locations

Country Name City State
United States Children's Healthcare of Atlanta - Emory University School of Medicine Atlanta Georgia
United States Section of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics and the Digestive Health Institute, Children's Hospital of Colorado and University of Colorado Aurora Colorado
United States Children's Mercy Kansas City, Department of Gastroenterology, Section of Hepatology Kansas City Missouri
United States Children's Hospital Los Angeles CHLA Los Angeles California
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States Children Hospital of Pittsburgh Pittsburgh Pennsylvania
United States Oregon Health and Science University, Division of Pediatric Gastroenterology, Department of Pediatrics Portland Oregon
United States University of Utah, Division of Pediatric Gastroenterology, Hepatology and Nutrition Salt Lake City Utah

Sponsors (1)

Lead Sponsor Collaborator
Mirum Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Long-term clinical outcome events The dates, and reasons for the following first events (of this first endpoint) will be collected: Surgical Biliary Diversion (SBD), Liver Transplant (LT), and all-cause mortality. In addition, manifestations of clinically evident portal hypertension will be captured during each interval event assessments. Long-term clinical outcomes (SBD, LT, portal hypertension, all-cause mortality) up to 180 days after discontinuation of Livmarli will be recorded.
Primary Liver Transplant Waitlist Status LT waitlist status will be collected, including when placed on or removed from an LT waitlist. LT waitlist status will be collected at enrollment and every 6 months for 5 years.
Primary Assessment of Height Height will be collected both at the time the participant started Livmarli and at the time of enrollment in the study. Subsequent height will be collected for up to 5 years.
Height z-score (centimeters) will be assessed and reported every year for 5 years.
Height z-score (centimeters) will be collected every year for 5 years.
Primary Assessment of Weight Weight will be collected both at the time the participant started Livmarli and at the time of enrollment in the study. Subsequent weight will be collected for up to 5 years.
Weight z-score (kilograms) will be assessed and reported every year for 5 years.
Weight z-score (kilograms) will be collected every year for 5 years.
Primary Incidence of Clinical Events Potentially Related to Fat-Soluble Vitamin Deficiencies Bleeding events (including all gastrointestinal [GI] or non-GI bleeding requiring hospitalization, emergency department care, or transfusion) and fracture events will be reported. The incidence of events will be assessed and reported every year for 5 years.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04729751 - A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). Phase 2
Active, not recruiting NCT05035030 - Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome Phase 3
Completed NCT02160782 - Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS) Phase 2
Completed NCT00007033 - Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease N/A
Suspended NCT00571272 - Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)
Completed NCT02057692 - Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome Phase 2
Active, not recruiting NCT02922751 - FibroScanā„¢ in Pediatric Cholestatic Liver Disease (FORCE)
Completed NCT00001642 - Positional Cloning of the Gene(s) Responsible for Alagille Syndrome N/A
Recruiting NCT05488067 - Atorvastatin Therapy on Xanthoma in Alagille Syndrome Phase 4
Completed NCT04674761 - Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome Phase 3
Completed NCT02117713 - An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome Phase 2
Completed NCT02131623 - Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease
Completed NCT02963077 - A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384 Phase 1
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Completed NCT03082937 - An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects Phase 1
Completed NCT02047318 - An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS) Phase 2
Completed NCT01903460 - Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome Phase 2
Completed NCT01515631 - Characterization of Pulmonary Artery Stenoses in Alagille Syndrome - a Medical Record Review
Enrolling by invitation NCT05846854 - Decreasing Hemorrhage Risk in Children With Alagille Syndrome N/A
Approved for marketing NCT04530994 - A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)